Pyxis Oncology, Inc. PYXS
We take great care to ensure that the data presented and summarized in this overview for Pyxis Oncology, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PYXS
View all-
Deep Track Capital, LP Greenwich, CT4.18MShares$6.44 Million0.57% of portfolio
-
Laurion Capital Management LP New York, NY3.63MShares$5.58 Million0.18% of portfolio
-
Black Rock Inc. New York, NY2.79MShares$4.29 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.43MShares$3.75 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.91MShares$2.94 Million0.0% of portfolio
-
Blue Owl Capital Holdings LP New York, NY1.13MShares$1.73 Million1.36% of portfolio
-
Geode Capital Management, LLC Boston, MA1.08MShares$1.67 Million0.0% of portfolio
-
Ikarian Capital, LLC Dallas, TX957KShares$1.47 Million0.61% of portfolio
-
State Street Corp Boston, MA951KShares$1.46 Million0.0% of portfolio
-
Abrdn PLC913KShares$1.41 Million0.01% of portfolio
Latest Institutional Activity in PYXS
Top Purchases
Top Sells
About PYXS
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at PYXS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 26
2024
|
Connealy Pamela Yanchik CFO & COO |
BUY
Open market or private purchase
|
Indirect |
88,850
+3.49%
|
$88,850
$1.98 P/Share
|
|
Jun 07
2024
|
Santhosh Palani |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+50.0%
|
-
|
|
Mar 26
2024
|
John L Flavin |
BUY
Grant, award, or other acquisition
|
Direct |
35,219
+7.86%
|
-
|
|
Mar 26
2024
|
Rachel Humphrey |
BUY
Grant, award, or other acquisition
|
Direct |
38,741
+28.58%
|
-
|
|
Mar 26
2024
|
Jakob Dupont |
BUY
Grant, award, or other acquisition
|
Direct |
38,741
+50.0%
|
-
|
|
Mar 26
2024
|
Freda C Lewis Hall |
BUY
Grant, award, or other acquisition
|
Direct |
35,219
+12.73%
|
-
|
|
Mar 26
2024
|
Darren S Cline |
BUY
Grant, award, or other acquisition
|
Direct |
35,219
+12.29%
|
-
|
|
Mar 26
2024
|
Connealy Pamela Yanchik CFO & COO |
BUY
Grant, award, or other acquisition
|
Direct |
328,710
+22.84%
|
-
|
|
Mar 26
2024
|
Jitendra Wadhane SVP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
131,484
+24.81%
|
-
|
|
Nov 29
2023
|
Connealy Pamela Yanchik CFO & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
36,949
-4.51%
|
$36,949
$1.4 P/Share
|
|
Nov 15
2023
|
Jitendra Wadhane SVP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+13.03%
|
-
|
|
Sep 28
2023
|
Connealy Pamela Yanchik CFO & COO |
BUY
Open market or private purchase
|
Direct |
8,000
+0.97%
|
$8,000
$1.87 P/Share
|
|
Sep 27
2023
|
Connealy Pamela Yanchik CFO & COO |
BUY
Open market or private purchase
|
Direct |
6,426
+0.79%
|
$6,426
$1.85 P/Share
|
|
Sep 27
2023
|
Jitendra Wadhane SVP, Chief Accounting Officer |
BUY
Open market or private purchase
|
Direct |
2,500
+1.09%
|
$2,500
$1.87 P/Share
|
|
Sep 25
2023
|
Jitendra Wadhane SVP, Chief Accounting Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+2.18%
|
$5,000
$1.77 P/Share
|
|
Sep 25
2023
|
Connealy Pamela Yanchik CFO & COO |
BUY
Open market or private purchase
|
Direct |
12,000
+1.47%
|
$12,000
$1.67 P/Share
|
|
Sep 22
2023
|
Connealy Pamela Yanchik CFO & COO |
BUY
Open market or private purchase
|
Direct |
5,000
+0.63%
|
$5,000
$1.74 P/Share
|
|
Sep 22
2023
|
Jitendra Wadhane SVP, Chief Accounting Officer |
BUY
Open market or private purchase
|
Direct |
2,500
+1.13%
|
$2,500
$1.74 P/Share
|
|
Sep 18
2023
|
Lara Sullivan Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
8,541
-0.35%
|
$17,082
$2.1 P/Share
|
|
Sep 14
2023
|
Lara Sullivan Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
100
-0.0%
|
$200
$2.25 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 649K shares |
|---|---|
| Open market or private purchase | 88.9K shares |